In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
CFDC
MIC
multidrug-resistant bacteria
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 Oct 2022
04 Oct 2022
Historique:
received:
12
08
2022
revised:
28
09
2022
accepted:
28
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated the in vitro activity of cefiderocol and comparators against multidrug-resistant (MDR) bacteria including meropenem-resistant (MR) or pandrug-resistant (PR) GN clinical isolates from France and Belgium. The minimum inhibitory concentrations (MICs) of CFDC were determined by broth microdilution, using iron-depleted cation-adjusted Mueller-Hinton broth, and were compared to those of 10 last-line antibiotics. The MICs were interpreted according to EUCAST and CLSI breakpoints, and in the absence of species-specific breakpoints, non-species-related pharmacokinetic/pharmacodynamic breakpoints were used. Among the 476 isolates tested, 322 were carbapenemase producers (CP), 58 non-CP-CRs, 52 intrinsically CR, 41 expanded-spectrum cephalosporin resistant and 5 were multi-susceptible. Susceptibility to CFDC was high using EUCAST breakpoints 81%, 99% and 84%, and was even higher using CLSI breakpoints to 93%, 100% and 88% for Enterobacterales,
Identifiants
pubmed: 36290010
pii: antibiotics11101352
doi: 10.3390/antibiotics11101352
pmc: PMC9598183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Shionogi & Co., Ltd
ID : Grant in aid
Organisme : Ministère de l'Éducation Nationale, de la Formation Professionnelle, de l'Enseignement Supérieur et de la Recherche Scientifique
ID : U1184
Organisme : Assistance Publique - Hôpitaux de Paris
ID : U1184
Références
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630181
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32727829
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 32958717
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7396-7401
pubmed: 27736756
Infect Dis Ther. 2022 Apr;11(2):853-870
pubmed: 35184255
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Eur J Clin Pharmacol. 2015 Jul;71(7):801-10
pubmed: 26008213
J Antimicrob Chemother. 2010 Feb;65(2):233-8
pubmed: 19996144
Pharmacotherapy. 2022 Mar;42(3):268-271
pubmed: 35075683
mSphere. 2019 Mar 27;4(2):
pubmed: 30918055
Med Mal Infect. 2020 Nov;50(8):715-722
pubmed: 32113869
JAC Antimicrob Resist. 2020 Aug 25;2(3):dlaa060
pubmed: 34223017
J Antimicrob Chemother. 2016 Mar;71(3):670-7
pubmed: 26645269
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4384-6
pubmed: 27139465
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
J Antimicrob Chemother. 2018 Nov 1;73(11):3049-3052
pubmed: 30188999
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024
pubmed: 32941593
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27821456
Int J Antimicrob Agents. 2019 Apr;53(4):456-466
pubmed: 30471402
Expert Rev Anti Infect Ther. 2022 May;20(5):707-719
pubmed: 34937518
Virulence. 2017 May 19;8(4):427-439
pubmed: 27168451
Clin Infect Dis. 2022 Aug 25;75(2):187-212
pubmed: 35439291
Clin Microbiol Infect. 2022 Apr;28(4):521-547
pubmed: 34923128
Front Microbiol. 2019 Jan 30;10:80
pubmed: 30761114
Emerg Infect Dis. 2021 Apr;27(4):1206-1210
pubmed: 33755001
Clin Microbiol Infect. 2021 Aug;27(8):1172.e7-1172.e10
pubmed: 33915286
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Antibiotics (Basel). 2022 Jan 31;11(2):
pubmed: 35203791
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862330
Sci Rep. 2020 Jan 17;10(1):589
pubmed: 31953453
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9
pubmed: 26926648
J Glob Antimicrob Resist. 2020 Dec;23:292-296
pubmed: 33065329
Microbiol Insights. 2019 Apr 04;12:1178636119840367
pubmed: 30992668
JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab081
pubmed: 34223140
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30323035
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500
pubmed: 27161636
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084
pubmed: 35148378
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319-2327
pubmed: 28748397
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722
pubmed: 35980232
J Hosp Infect. 2009 Dec;73(4):338-44
pubmed: 19699552
Microbiol Spectr. 2022 Apr 27;10(2):e0008422
pubmed: 35323031
Clin Infect Dis. 2011 Jul 1;53(1):60-7
pubmed: 21653305
J Antimicrob Chemother. 2020 May 1;75(5):1165-1173
pubmed: 32040168
J Antimicrob Chemother. 2019 Aug 1;74(8):2239-2246
pubmed: 31127297
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021
pubmed: 34606331
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29061741